| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966369 | Vaccine | 2013 | 6 Pages |
Abstract
This model provides a “benchmark” for assessing progress in the prevention of IPD in the years after PCV13 introduction. The amount of serotype replacement is unlikely to greatly affect the overall number of cases prevented by PCV13.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ruth Link-Gelles, Thomas Taylor, Matthew R. Moore, for the Active Bacterial Core Surveillance Team for the Active Bacterial Core Surveillance Team,